Notices. Single-Source Permanent Replacement Grant

6,153 words·~28 min read·/register/2007/10/12/07-5051

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4150-33-M DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Update of A Public Health Action Plan To Combat Antimicrobial Resistance The Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and National Institutes of Health

(NIH)announce an open meeting concerning antimicrobial resistance. *Name:* Update of A Public Health Action Plan To Combat Antimicrobial Resistance. *Times and Dates:* 8:30 a.m.-6 p.m., December 12, 2007; 8 a.m.-3 p.m., December 13, 2007. *Place:* Grand Hyatt Atlanta in Buckhead, 3300 Peachtree Road, Atlanta, Georgia, USA 30305. Tel: +1 404/237-1234, Fax: +1 404/233-5686. *Status:* Open to the public, limited only by the space available. *Purpose:* To solicit input from invited consultants to update A Public Health Action Plan To Combat Antimicrobial Resistance that, when published in 2001, provided a blueprint for activities of Federal agencies to combat antimicrobial resistance. The Plan was developed by consultants from multi-disciplines and the Antimicrobial Resistance Task Force, composed of Federal personnel from ten Federal agencies and departments, co-chaired by CDC, FDA, and NIH. The revised Plan will not be limited to domestic activities. *Matters To Be Discussed:* The agenda will focus on updates and revisions of existing action items or the addition of new items to the Plan. Action items in A Public Health Action Plan To Combat Antimicrobial Resistance are presented in four major topics: 1. Surveillance. 2. Prevention and Control. 3. Research. 4. Product Development. Comments and suggestions from the consultants for updates of specific action items in the Action Plan or addition of new action items in these topics will be taken under advisement by the Task Force. The Task Force may also utilize other sources of information in updating the Action Plan. The agenda does not include development of consensus positions, guidelines, or discussions or endorsements of specific commercial products. Agenda items are subject to change as priorities dictate. Limited time will be available for oral comments and suggestions from the public. Written comments and suggestions from the public are encouraged and should be received by the contact person listed below by December 3, 2007. Persons anticipating attending the meeting are requested to send written notification by December 3, 2007, including name, organization (if applicable), address, phone, fax, and email addresses to the contact below. *For Further Information Contact:* Gregory J. Anderson, Centers for Disease Control and Prevention (CDC), Office of Antimicrobial Resistance, Mailstop A-07, 1600 Clifton Road, NE., Atlanta, Georgia 30333. Telephone +1 404/639-3539, fax +1 404/639-7444, e-mail: *gca5@cdc.gov.* Dated: October 4, 2007. James D. Seligman, Chief Information Officer, Centers for Disease Control and Prevention. [FR Doc. E7-20125 Filed 10-11-07; 8:45 am] BILLING CODE 4163-18-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [Document Identifier: CMS-10185, CMS-10137, CMS-10240, CMS-10237 and 10214, CMS-855, and CMS-R-39] Agency Information Collection Activities: Submission for OMB Review; Comment Request AGENCY: Centers for Medicare & Medicaid Services, HHS. In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects:

(1)The necessity and utility of the proposed information collection for the proper performance of the Agency's function;

(2)the accuracy of the estimated burden;

(3)ways to enhance the quality, utility, and clarity of the information to be collected; and

(4)the use of automated collection techniques or other forms of information technology to minimize the information collection burden. 1. *Type of Information Collection Request:* Revision of a currently approved collection; *Title of Information Collection:* Medicare Part D Reporting Requirements and Supporting Regulations under 42 CFR section 423.505; *Form Number:* CMS-10185 (OMB#: 0938-0992); *Use:* 42 CFR 423.514, requires each Part D Sponsor to have an effective procedure to provide statistics indicating: The cost of its operations, the patterns of utilization of its services, the availability, accessibility, and acceptability of its services, information demonstrating it has a fiscally sound operation and other matters as required by CMS. In addition, § 423.505 of the regulation, establishes a contract provision that Part D Sponsors must comply with the reporting requirements for submitting drug claims and related information to CMS. Data collected via Medicare Part D Reporting Requirements will be an integral resource for oversight, monitoring, compliance and auditing activities necessary to ensure quality provision of the Medicare Prescription Drug Benefit to beneficiaries. Refer to the “Revisions from 60-day Comment Period to CY 2008 Part D Reporting Requirements” document to view a list of current changes. *Frequency:* Reporting—Monthly, Annually, Quarterly and Semi-annually; *Affected Public:* Business or other for-profit; *Number of Respondents:* 4,857; *Total Annual Responses:* 330,276; *Total Annual Hours:* 287,132. 2. *Type of Information Collection Request:* Revision of a currently approved collection; *Title of Information Collection:* Application for Prescription Drug Plans (PDP); Application for Medicare Advantage Prescription Drug (MA-PD); Application for Cost Plans to Offer Qualified Prescription Drug Coverage; Application for Employer Group Waiver Plans to Offer Prescription Drug Coverage; Service Area Expansion Application for Prescription Drug Coverage; *Use:* Collection of this information is mandated in Part D of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. The application requirements are codified in Subpart K of 42 CFR 423. Coverage for the prescription drug benefit is provided through prescription drug plans

(PDPs)that offer drug-only coverage, or through Medicare Advantage

(MA)organizations that offer integrated prescription drug and health care coverage (MA-PD plans). PDPs must offer a basic drug benefit. Medicare Advantage Coordinated Care Plans (MA-CCPs) must offer either a basic benefit or may offer broader coverage for no additional cost. Medicare Advantage Private Fee for Service Plans (MA-PFFS) may choose to offer a Part D benefit. Cost Plans that are regulated under Section 1876 of the Social Security Act, and Employer Group Plans may also provide a Part D benefit. If any of the contracting organizations meet basic requirements, they may also offer supplemental benefits through enhanced alternative coverage for an additional premium. The information will be collected under the solicitation of proposals from PDP, MA-PD, Cost Plan, and Employer Group Waiver Plans applicants. The collected information will be used by CMS to:

(1)Insure that applicants meet CMS requirements, and

(2)support the determination of contract awards. Refer to the “High-Level Summary of Changes in Employer/Union Group Waiver Plan Part D Applications” and “High-Level Summary of All Part D Application Revisions from 2008 Solicitation for the 2009 Solicitation” documents to review a list of changes from 2008 to 2009; *Form Number:* CMS-10137 (OMB#: 0938-0936); *Frequency:* Reporting: Once; *Affected Public:* Business or other for-profit and Not-for-profit institutions; *Number of Respondents:* 455; *Total Annual Responses:* 455; *Total Annual Hours:* 11,890. 3. *Type of Information Collection Request:* New collection; *Title of Information Collection:* Data Collection for the Nursing Home Value-Based Purchasing (NHVBP) Demonstration; *Use:* The NHVBP Demonstration is a CMS “pay-for-performance” initiative to improve the quality of care furnished to Medicare beneficiaries residing in nursing homes. Under this three-year demonstration project, CMS will assess the performance of nursing homes based on selected quality measures, and then make additional payments to those nursing homes that achieve a higher performance based on those measures. In the first year of the demonstration, quality will be assessed based on the following four domains: Staffing, appropriate hospitalizations, outcome measures from the minimum data set (MDS), and survey deficiencies. Additional quality measures may be added in the second and third years of the demonstration as deemed appropriate. The main purpose of the NHVBP data collection effort is to gather information that will enable CMS to determine which nursing homes will be eligible to receive incentive payments under the NHVBP Demonstration. All measures included in the MDS outcomes, survey deficiency, and appropriate hospitalization domains can be calculated from existing secondary data sources, such as the MDS, annual nursing home certification surveys, and Medicare claims data. However, for the staffing domain, no satisfactory alternative source for these data has been identified. Therefore, CMS will collect payroll-based staffing and resident census information to help assess the quality of care in participating nursing homes. CMS will additionally collect data on two measures, staff immunization status and use of resident care experience surveys, which may be included in the payment determination during the second and third years of the demonstration. Refer to the “Summary of Changes to Data collection for the Nursing Home Value-Based Purchasing (NHVBP) Demonstration” documents to review a list of changed items. *Form Number:* CMS-10240 (OMB#: 0938-New); *Frequency:* Reporting: Once; *Affected Public:* Business or other for-profit and Not-for-profit institutions; *Number of Respondents:* 1,250; *Total Annual Responses:* 2,000; *Total Annual Hours:* 49,170. 4. *Type of Information Collection Request:* Revision of a currently approved collection; *Title of Information Collection:* Medicare Advantage

(MA)Applications—Part C; *Use:* An entity seeking a contract as an MA organization must be able to provide Medicare's basic benefits plus meet the organizational requirements set out in regulations at 42 CFR Part 422. An applicant must demonstrate that it can meet the benefit and other requirements within the specific geographic area it is requesting. The application forms are designed to give CMS the information they need about the health plan to determine compliance with Federal regulations at 42 CFR Part 422 in an efficient manner. The cited regulations outline the MA application process that begins with submission of an application in the form and manner that the Secretary provides. The MA application forms will be used by CMS to determine whether an entity is eligible to enter into a contract to provide services to Medicare beneficiaries. Refer to the “High Level Summary of Key Changes Between The 2008 Part C Applications and The 2009 Part C Applications” and the “High-Level Summary of Changes in Employer/Union-Only Group Waiver Plan MAO Applications” documents to review a list of the changes. *Form Number:* CMS-10237 and 10214 (OMB#: 0938-0935); *Frequency:* Reporting: Yearly; *Affected Public:* Business or other for-profit and Not-for-profit institutions; *Number of Respondents:* 241; * Total Annual Responses: * 241; *Total Annual Hours:* 5858. 5. *Type of Information Collection Request:* Extension of a currently approved collection; *Title of Information Collection:* Medicare Enrollment Application; *Form Number:* CMS-855 (OMB#: 0938-0685); *Use:* The primary function of the Medicare enrollment application is to gather information from a provider or supplier that tells us who it is, whether it meets certain qualifications to be a health care provider or supplier, where it practices or renders its services, the identity of the owners of the enrolling entity, and information necessary to establish the correct claims payment. The goal of evaluating and revising the Medicare enrollment applications is to simplify and clarify the information collection without jeopardizing our need to collect specific information. We are proposing revisions to the CMS-855B to incorporate changes adopted in CMS-1321-FC (71 FR 69624), “Revisions to Payment Policies and Five-Year Review of Relative Value Units Under the Physician Fee Schedule for CY 2007 and Other Changes to Payment Under Part B; Revisions to Ambulance Fee Schedule; Ambulatory Inflation Factor Update for CY 2007.” Specifically, CMS is revising the CMS-855B to: • Add instructions to Attachment 2 that explain the independent diagnostic testing facility

(IDTF)liability insurance requirements in 42 CFR § 410.33(g)(6). • Require that an IDTF submit copies of its comprehensive liability insurance policy in Section 17. • List all of the new IDTF standards on a separate page in Attachment 2. • Remove the supplier type “Voluntary Health/Charitable Agency” from Section 2A. In addition, we are trying to enhance our ability to identify whether a hospital qualifies as a “specialty hospital.” To this end, we propose to revise the CMS-855A to include a specific box that specialty hospitals must check when completing the application. Instructions explaining the definition of a “specialty hospital” will also be added to the form. We also provide clarification of the term “primary practice location” in the instructions in Section 4 of the CMS-855A. This clarification does not change any data elements on the form. We are also removing the data element “Medicare Year-End Cost Report Date” in Section 2 of the CMS-855A, as this information is no longer needed. *Frequency:* Recordkeeping and Reporting—On occasion; *Affected Public:* Business or other for-profit and Not-for-profit institutions; *Number of Respondents:* 400,000; *Total Annual Responses:* 400,000; *Total Annual Hours:* 1,001,503.33. 6. *Type of Information Collection Request:* Extension of a currently approved collection; *Title of Information Collection:* Home Health Conditions of Participation

(CoP)Information Collection Requirements and Supporting Regulations in 42 CFR 484.10, 484.12, 484.16, 484.18, 484.36, 484.48, 484.52; *Form Numbers:* CMS-R-39 (OMB#: 0938-0365); *Use:* The information collection requirements contained in this request are part of the requirements classified as the conditions of participation

(CoPs)which are based on criteria prescribed in law and are standards designed to ensure that each facility has properly trained staff to provide the appropriate safe physical environment for patients. These particular standards reflect comparable standards developed by industry organizations such as the Joint Commission on Accreditation of Healthcare Organizations, and the Community Health Accreditation Program. The primary users of this information will be State agency surveyors, the regional home health intermediaries, CMS and home health agencies

(HHAs)for the purpose of ensuring compliance with Medicare CoPs as well as ensuring the quality of care provided by HHA patients. *Frequency:* Recordkeeping and Reporting—Annually, On occasion; *Affected Public:* Business or for-profits, Not-for-profit institutions, and State, Local or Tribal governments; *Number of Respondents:* 9,354; *Total Annual Responses:* 9,354; *Total Annual Hours:* 1,048,483.5. To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access CMS Web Site address at *http://www.cms.hhs.gov/PaperworkReductionActof1995* , or e-mail your request, including your address, phone number, OMB number, and CMS document identifier, to *Paperwork@cms.hhs.gov* , or call the Reports Clearance Office on

(410)786-1326. To be assured consideration, comments and recommendations for the proposed information collections must be received by the OMB desk officer at the address below, no later than 5 p.m. on *November 13, 2007.* OMB Human Resources and Housing Branch, Attention: Carolyn Lovett, New Executive Office Building, Room 10235, Washington, DC 20503, Fax Number:

(202)395-6974. Dated: October 4, 2007. Michelle Shortt, Director, Regulations Development Group, Office of Strategic Operations and Regulatory Affairs. [FR Doc. E7-20150 Filed 10-11-07; 8:45 am] BILLING CODE 4120-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children And Families Administration on Children, Youth, and Families, Children's Bureau; Single-Source Permanent Replacement Grant AGENCY: Children's Bureau, Administration on Children, Youth and Families, Administration for Children and Families; Department of Health and Human Services. ACTION: Single-Source Permanent Replacement Grant. *CFDA#:* 93.648. *Legislative Authority:* Child Welfare Training [Section IV-B, section 426

(a)1

(C)of the Social Security Act] *Amount of Award:* $200,000 per year for one year. *Project Period:* 9/30/2007-9/29/2008. *Justification for the Exception to Competition:* Sonoma State University, California Institute on Human Services, Rohnert Park, CA, (the grantee) has relinquished their grant entitled, “Training for Effective Child Welfare Practice in Rural Communities,” funded under the Child Welfare Training program. San Jose State University Research Foundation, San Jose, CA, has been authorized as permanent successor grantee for this project. The Project Director under the former grantee will continue in the same capacity with San Jose State University Research Foundation. Awarding these funds will allow the project to complete their goals and objectives as originally approved. FOR FURTHER INFORMATION CONTACT: Jan P. Shafer, Children's Bureau, Portals Building, Suite 800, 1250 Maryland Avenue, SW., Washington, DC 20024. Telephone: 202-205-8172. Dated: October 3, 2007. Joan E. Ohl, Commissioner, Administration on Children, Youth and Families. [FR Doc. E7-20094 Filed 10-11-07; 8:45 am] BILLING CODE 4184-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Medical Device User Fee Rates for Fiscal Year 2008 AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration

(FDA)is publishing the fee rates and payment procedures for medical device user fees for fiscal year

(FY)2008. The Federal Food, Drug, and Cosmetic Act (the act), as amended by the Medical Device User Fee and Modernization Act of 2002 (MDUFMA), the Medical Device User Fee Stabilization Act of 2005 (MDUFSA), and the Medical Device User Fee Amendments of 2007 (Title II of the Food and Drug Administration Amendments Act of 2007 (FDAAA)), authorizes FDA to collect user fees for certain medical device submissions, and annual fees both for certain periodic reports and for certain establishments subject to registration. The FY 2008 fee rates are provided in this notice. These fees apply from October 1, 2007, through September 30, 2008. To avoid delay in the review of your application, you should pay the fee before or at the time you submit your application to FDA. The fee you must pay is the fee that is in effect on the later of the date that your application is received by FDA or the date your fee payment is received. If you want to pay a reduced small business fee, you must qualify as a small business before you make your submission to FDA; if you do not qualify as a small business before you make your submission to FDA, you will have to pay the higher standard fee. This notice provides information on how the fees for FY 2008 were determined, the payment procedures you should follow, and how you may qualify for reduced small business fees. FOR FURTHER INFORMATION CONTACT: *For further information on MDUFMA* : Visit FDA's Web site, *http://www.fda.gov/cdrh/mdufma* . *For questions relating to this notice* : Yanming Chae, Office of Financial Management (HFA-120), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-5042. SUPPLEMENTARY INFORMATION: I. Background Section 738 of the act (21 U.S.C. 379j) establishes fees for certain medical device applications, submissions, supplements, and notices (for simplicity, this notice refers to these collectively as “submissions”); for periodic reporting on class III devices; and for the registration of certain establishments. Under statutorily defined conditions, a qualified applicant may receive a fee waiver or may pay a lower small business fee (see 21 U.S.C. 379j(d) and (e)). Under the act, the fee rate for each type of submission is set at a specified percentage of the standard fee for a premarket application (a premarket application is a premarket approval application (PMA), a product development protocol (PDP), or a biologics licensing application (BLA)). The act specifies the standard fee for a premarket application for each year from FY 2008 through FY 2012; the standard fee for a premarket application received by FDA during FY 2008 is $185,000. From this starting point, this notice establishes FY 2008 fee rates for other types of submissions, and for periodic reporting, by applying criteria specified in the act. The act specifies the annual fee for establishment registration for each year from FY 2008 through FY 2012; the registration fee for FY 2008 is $1,706. There is no reduction in the registration fee for small businesses. An establishment must pay the annual registration fee if it is any of the following types of establishments: • *Manufacturer* . An establishment that makes by any means any article that is a device, including an establishment that sterilizes or otherwise makes such article for or on behalf of a specification developer or any other person. • *Single-use device reprocessor* . An establishment that performs manufacturing operations on a single-use device that has previously been used on a patient. • *Specification developer* . An establishment that develops specifications for a device that is distributed under the establishment's name but which performs no manufacturing, including an establishment that, in addition to developing specifications, also arranges for the manufacturing of devices labeled with another establishment's name by a contract manufacturer. The fees for FY 2008 go into effect on October 1, 2007, and will remain in effect through September 30, 2008. II. Fees for FY 2008 Under the act, all submission fees and the periodic reporting fee are set as a percent of the standard

(full)fee for a premarket application (see 21 U.S.C. 379j(a)(2)(A)), and the act sets the standard fee for a premarket application at $185,000 for FY 2008 (see 21 U.S.C. 379j(b); this is referred to as the “base fee”). The fees set by reference to the base (see 21 U.S.C. 379j(a)(2)(A)) fee are— • For a panel-track supplement, 75 percent of the base fee; • For a 180-day supplement, 15 percent of the base fee; • For a real-time supplement, 7 percent of the base fee; • For a 30-day notice, 1.6 percent of the base fee; • For a 510(k) premarket notification, 1.84 percent of the base fee; • For a 513(g) request for classification information, 1.35 percent of the base fee; and • For an annual fee for periodic reporting concerning a class III device, 3.5 percent of the base fee. For all submissions other than a 510(k) premarket notification, a 30-day notice, and a 513(g) request for classification information, the small business fee is 25 percent of the standard

(full)fee (see 21 U.S.C. 379j(d)(2)(C)). For a 510(k) premarket notification submission, a 30-day notice, and a 513(g) request for classification information, the small business fee is 50 percent of the standard

(full)fee (see 21 U.S.C. 379j(e)(2)(C) and (d)(2)(C), respectively). There is no small business rate for annual establishment registration fee; all establishments pay the same fee. Table 1 of this document sets out the FY 2008 rates for all medical device fees. **Table 1.—Medical Device Fees for FY 2008** Standard Fee, as a Percent of the Standard Fee for a Premarket Application FY 2008 Standard Fee FY 2008 Small Business Fee Application Fee Type Premarket application (a PMA submitted under section 515(c)(1) of the act (21 U.S.C. 360e(c)(1)), a PDP submitted under section 515(f) of the act, or a BLA submitted under section 351 of the Public Health Service

(PHS)Act (42 U.S.C. 262)) Set in statute $185,000 $46,250 Premarket report (submitted under section 515(c)(2) of the act) 100% $185,000 $46,250 Efficacy supplement (to an approved BLA under section 351 of the PHS act) 100% $185,000 $46,250 Panel-track supplement 75% $138,750 $34,688 180-day supplement 15% $27,750 $6,938 Real-time supplement 7% $12,950 $3,237 510(k) premarket notification submission 1.84% $3,404 $1,702 30-day notice 1.6% $2,960 $1,480 513(g) request for classification information 1.35% $2,498 $1,249 Annual Fee Type Annual fee for periodic reporting on a class III device 3.5% $6,475 $1,619 Annual establishment registration fee (to be paid by each establishment that is a manufacturer, a single-use device reprocessor, or a specification developer, as defined by 21 U.S.C. 379i(13)) Set in statute $1,706 $1,706 III. How to Qualify as a Small Business for Purposes of Medical Device Fees If your business has gross receipts or sales of no more than $100 million for the most-recent tax year, you may qualify for reduced small business fees. If your business has gross sales or receipts of no more than $30 million, you may also qualify for a waiver of the fee for your first premarket application (PMA, PDP, or BLA) or premarket report. You must include the gross receipts or sales of all of your affiliates along with your own gross receipts or sales when determining whether you meet the $100 million or $30 million threshold. If you want to pay the small business fee rate for a submission, or you want to receive a waiver of the fee for your first premarket application or premarket report, you should submit the materials showing you qualify as a small business 60 days before you send your submission to FDA. If you make a submission before FDA finds that you qualify as a small business, you must pay the standard fee for that submission. If your business qualified as a small business for FY 2007, your status as a small business will expire at the close of business on September 30, 2007. You must re-qualify for FY 2008 in order to pay fees at the small business rate during FY 2008. If you are a domestic (U.S.) business, and wish to qualify as a small business for FY 2008, you must submit the following to FDA:

(1)A completed FY 2008 MDUFMA Small Business Qualification Certification (Form FDA 3602). This form is provided in FDA's guidance document “FY 2008 Medical Device User Fee Small Business Qualification and Certification,” available on FDA's Web site at *http://www.fda.gov/cdrh/mdufma* . This form is not available separate from the guidance document.

(2)A certified copy of your Federal (U.S.) Income Tax Return for the most recent tax year (2006 or later).

(3)For each of your affiliates, either—

(A)If the affiliate is a domestic (U.S.) business, a certified copy of the affiliate's Federal (U.S.) Income Tax Return for the most recent tax year, or

(1)A completed FY 2008 MDUFMA Foreign Small Business Qualification Certification (Form FDA 3602A). This form is provided in FDA's guidance document “FY 2008 Medical Device User Fee Small Business Qualification and Certification,” available on FDA's Web site at *http://www.fda.gov/cdrh/mdufma* . This form is not available separate from the guidance document.

(2)A National Taxing Authority Certification, completed by, and bearing the official seal of, the National Taxing Authority of the country in which the firm is headquartered. This certification must show the amount of gross receipts or sales for the most recent tax year, in both U.S. dollars and the local currency of the country, the exchange rate used in converting the local currency to U.S. dollars, and the dates of the gross receipts or sales collected.

(3)For each of your affiliates, either—

(A)If the affiliate is a domestic (U.S.) business, a certified copy of the affiliate's Federal (U.S.) Income Tax Return for the most recent tax year (2006 or later), or

(B)If the affiliate is a foreign business and cannot submit a Federal (U.S.) Income Tax Return, a National Taxing Authority Certification completed by, and bearing the official seal of, the National Taxing Authority of the country in which the firm is headquartered. This certification must show the amount of gross receipts or sales for the most recent tax year, in both U.S. dollars and the local currency of the country, the exchange rate used in converting the local currency to U.S. dollars, and the dates of the gross receipts or sales collected. The applicant should also submit a statement signed by the head of the applicant's firm or by its chief financial officer that the applicant has submitted certifications for all of its affiliates, identifying the name(s) of each affiliate(s), or that the applicant has no affiliates. The National Taxing Authority is the foreign equivalent of the U.S. Internal Revenue Service. IV. Procedures for Paying Application and Annual Report Fees If your application or submission is subject to a fee and is received by FDA from October 1, 2007, through September 30, 2008, you must pay the fee in effect for FY 2008. The later of the date that the application or annual report is received in the reviewing center's document room or the date that the check is received by US Bank determines whether the fee rates for FY 2007 or FY 2008 apply. FDA must receive the correct fee at the time that an application or annual report is submitted, or the application or annual report will not be accepted for filing or review. FDA requests that you follow the steps in this section before submitting a medical device application or annual report subject to a fee. Please pay close attention to these procedures to ensure that FDA links the fee with the correct application. (Note: In no case should the check for the fee be submitted to FDA with the application.) A. Step One—Secure a Payment Identification Number and Medical Device User Fee Cover Sheet From FDA Before Submitting Either the Application or the Payment. Note: FY 2008 fee rates will be available on the Cover Sheet Web site beginning on the date of publication of this notice Log onto the MDUFMA Web site at *http://www.fda.gov/oc/mdufma* and, under the forms heading, click on the link “User Fee Cover Sheet.” Complete the Medical Device User Fee Cover Sheet. Be sure you choose the correct application submission date range. After completing data entry, print a copy of the Medical Device User Fee Cover Sheet and note the unique Payment Identification Number located in the upper right-hand corner of the printed cover sheet. B. Step Two—Electronically Transmit a Copy of the Printed Cover Sheet with the Payment Identification Number to FDA's Office of Financial Management Once you are satisfied that the data on the cover sheet is accurate, electronically transmit that data to FDA according to instructions on the screen. Because electronic transmission is possible, applicants are required to set up a user account and use passwords to assure data security in the creation and electronic submission of cover sheets. C. Step Three—Mail Payment and a Copy of the Completed Medical Device User Fee Cover Sheet to the St. Louis Address Specified in This Section • Make the payment in U.S. currency by check, bank draft, or U.S. Postal money order payable to the Food and Drug Administration. (FDA's tax identification number is 53-0196965, should your accounting department need this information.) • Please write your application's unique Payment Identification Number, from the upper right-hand corner of your completed Medical Device User Fee Cover Sheet, on your check, bank draft, or U.S. Postal money order. • Mail the payment and a copy of the completed Medical Device User Fee Cover Sheet to: Food and Drug Administration, P.O. Box 956733, St. Louis, MO 63195-6733. (Please note that this address is for payments of application and annual report fees only and is not to be used for payment of annual establishment registration fees.) If you prefer to send a check by a courier (such as FEDEX, DHL, UPS, etc.), the courier may deliver the check to: US Bank, Attn: Government Lockbox 956733, 1005 Convention Plaza, St. Louis, MO 63101. (Note: This address is for courier delivery only. Contact the US Bank at 314-418-4821 if you have any questions concerning courier delivery.) It is helpful if the fee arrives at the bank at least 1 day before the application arrives at FDA. FDA records the official application receipt date as the later of the following: • The date the application was received by FDA. • The date US Bank receives the payment. US Bank is required to notify FDA within 1 working day, using the Payment Identification Number described previously. D. Step Four—Submit Your Application to FDA with a Copy of the Completed Medical Device User Fee Cover Sheet Please submit your application and a copy of the completed Medical Device User Fee Cover Sheet to one of the following addresses: • Medical device applications should be submitted to: Food and Drug Administration, Center for Devices and Radiological Health, Document Mail Center (HFZ-401), 9200 Corporate Blvd., Rockville, MD 20850. • Biologic applications should be sent to: Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center (HFM-99), suite 200N, 1401 Rockville Pike, Rockville, MD 20852-1448. V. Procedures for Paying Annual Establishment Fees Procedures for paying annual establishment fees are different from the previously mentioned procedures for paying application, submission, and annual report fees. An establishment is not legally registered in FY 2008 until it has both completed the following steps to register and paid any fee that may be applicable (see 21 U.S.C. 379j(f)(2)). A. Step One—Complete the Information Online to Update Your Establishment's Registration for FY 2008, or to Register a New Establishment for FY 2008 Log onto CDRH's Web site at *http://www.fda.gov/cdrh/reglistpage.html* and follow the link from that page to the FDA Unified Registration and Listing System (FURLS). If you already have a registered medical device establishment, FDA has sent you a letter that contains your account ID and password for logging into FURLS. If you are an owner or operator registering for the first time, you will need to create a FURLS account. There are tutorials available from the FURLS/FDA Industry Systems homepage that demonstrate how to create FURLS user accounts. Once you obtain your account ID and password, you will enter them and log into FURLS. From the FURLS/FDA Industry Systems menu, there will be a button that you will click to go to the Device Registration and Listing Module

(DRLM)of FURLS. New establishments will register their establishment and existing establishments will re-register their establishments using choices on the DRLM menu. Once you make your selection—either Register a Facility or Annual Re-registration—the system will prompt you through the entry of information about your establishment and your devices. If you have any problems with this process you may call 240-276-0111 for assistance. (Note: This phone number is for assistance with establishment registration and establishment fee payment only, and not for any other aspects of medical device user fees.) B. Step Two—Determine Whether an Annual Registration Fee is Required and Get Your Invoice if a Fee is Due After you enter your establishment registration information into the system, you will be informed whether or not the payment of an annual registration fee is required to complete your registration (these fees are only required for device manufacturers, single-use re-processors, and specification developers as stated in section I of this document). If your establishment is subject to a fee, you will be given a summary sheet that:

(1)Tells you what your payment options are and

(2)leads you to a link for your specific invoice, which will be available on-line as a portable document format

(PDF)file that you should print copies of; one to submit with your payment (if not submitted electronically) and the other to keep for your records. C. Step Three—Pay Your Invoice, if Required Make the payment, if required, in U.S. currency. The summary page will include payment information that may permit you the option of paying electronically. If that option is provided, you may follow the instructions provided to make payment electronically. If that option is not provided, or you choose not to make your payment electronically, you may pay by check. Your check, made in U.S. dollars and drawn on a U.S. bank, can be mailed to: Food and Drug Administration, P.O. Box 70961, Charlotte, NC 28272-0961. (Please note that this is different than the address for payments of application and annual report fees and is to be used only for payment of annual establishment registration fees.) If checks are to be sent by a courier that requests a street address, the courier can deliver the checks to: Wachovia Bank, Attn: Food and Drug Administration—Lockbox 70961, rm. NC0810, 1525 West WT Harris Blvd., Charlotte, NC 28262. (Note: This Wachovia Bank address is for courier delivery only; do not send mail to this address.) Please make sure that the FDA post office box number (P.O. Box 70961) is written on the check, along with the invoice number printed on your invoice. A copy of your printed invoice should also be mailed in the same envelope with your check. FDA's tax identification number is 53-0196965. Wire transfers may also be used to pay annual establishment fees. The routing and transit number is 021030004 and the account number is 75060099. The invoice number should also be included with any wire transfer information, to assure that the invoice is properly credited. FDA is in the process of implementing alternate Web-based payment methods, and the option of electronic payment may not be immediately available for FY 2008 payments. For more information on these payment options and when they will be available, please visit FDA's Web site at *http://www.fda.gov* , select the appropriate user fee type, and click on “User Fee Cover Sheet.” Dated: October 4, 2007. Randall W. Lutter, Deputy Commissioner for Policy. [FR Doc. 07-5051 Filed 10-9-07; 12:06 pm]

Connectionstraces to 4

Traces to 4 documents

U.S. Code

6 references not yet in our index